Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A History of the Science, Treatment of Rheumatologic Illnesses from Gold to Gene Therapy

Simon M. Helfgott, MD  |  Issue: December 2017  |  December 17, 2017

Mysterious Ways

The juxtaposition of the old and the new was readily evident that busy Wednesday morning. My first patient, a 94-year-old gentleman, Hal, arrived with a precise request. His rheumatologist for the past 40 years had just retired, and he was searching for a doctor with expertise in the use of gold sodium aurothioglucose, the drug that had driven his rheumatoid arthritis (RA) into remission decades before.

Whether it was based on fact or superstition, we were taught that if gold induced a state of low disease activity, it should never be stopped. The lucky few patients who achieved remission would return monthly for their injections, ad infinitum.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Hal described the marvelous benefits of gold, and he was mystified as to why this “wonder drug” had become so difficult to procure. Although he located a pharmacy that sold an injectable gold salt product, it was of a different variety, gold sodium thiomalate (GST), a formulation that caused him great distress, with symptoms of nausea and flushing following each injection, reminiscent of the irksome nitritoid reaction, a well-recognized side effect of chrysotherapy that occurred in roughly 5% of patients taking GST.1

Hal’s physical findings were few; his joint exam findings were negligible; and his pale complexion belied his many decades of gold salt use, because there was no chrysiasis, the telltale slate-grey skin pigmentation that often identified the recipient of gold therapy to the knowledgeable eye.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As I was meeting Hal, one of our fellows was busy disassembling a complicated tale from her new patient, Dawn, a woman about a quarter Hal’s age, whose lifelong juvenile idiopathic arthritis provided ample evidence of ongoing synovitis and prior joint damage. Over the years, the various synthetic and biologic disease-modifying drugs that stock our modern-day armamentarium had been prescribed, achieving scant success.

How odd to juxtapose the successful outcome observed in one patient who was prescribed an ancient, heavy-metal nostrum, whose mode of action in RA was poorly understood, with the failure in another patient of our newest, targeted therapies, whose constructs were based upon our sophisticated knowledge of modern-day immunology.

These anomalous outcomes serve as a reminder that medicine can still move in mysterious ways (with an homage to Bono and U2!).3 Fortunately, we are making great strides in disassembling both the innate and adaptive arms of the immune response, allowing a clearer insight into the complexities of the autoimmune responses. The accretion of knowledge that has dramatically transformed our clinical practice over the past 70-odd years can be traced to a sequence of revolutions in the clinical and basic sciences.

A Series of Revolutions

The first revolution occurred following the end of the first World War, about the time when rheumatology began organizing into a distinct specialty. Previously, clinicians with an interest in rheumatic disease tended to come from one of two fields: infectious diseases, because a commonly held belief at the time was the critical role that mycobacteria and bacteria played in the pathogenesis of chronic forms of arthritis and inflammation, and the field of physical medicine, in particular medical hydrology, a long-lost discipline that sought to incorporate the use of saunas, spas and whirlpools into clinical practice. What a life!.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:American College of Rheumatology (ACR)American Rheumatism AssociationArthritisautoimmune mediated diseasebioinformaticsC-reactive proteinClinicalcorticosteroid drugsDiagnosisgenomicsHistoryimmune-suppressive therapiesinflammationknowledgemedicalpatient careResearchRheumatic Diseaserheumatologysciencetranslational researchTreatment

Related Articles

    Metrics in Rheumatology: Focus on Harold E. (Hal) Paulus, MD

    April 11, 2019

    We have just learned that Dr. Hal Paulus passed away on April 5, 2019. We are reposting this story today in his memory and will share additional information as we learn it.

    A Short History of Rheumatoid Arthritis Therapeutics

    January 13, 2012

    Or, why I chose to become a rheumatologist

    Cardiovascular Risk in Tocilizumab Therapy for RA

    September 15, 2015

    Observation and research have confirmed that patients with rheumatoid arthritis (RA) are at greater risk of cardiovascular disease than their peers of similar age and gender, and that traditional risk factors and chronic inflammation associated with RA apparently play a significant role in that risk. However, predicting which patients with rheumatoid arthritis are at greater…

    When Rheumatic Disease May Have Affected the Course of Western Civilization

    November 8, 2022

    The study of rheumatology (and medicine) in art, history, literature and music is engaging and informative.1-12 In this article, we present some instances when rheumatic and autoimmune diseases in certain individuals may have affected the course of history in Western civilization. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEPhysicians are usually concerned, appropriately, with the effects of illness…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences